Psilocybin – Summary of knowledge and new perspectives

  title={Psilocybin – Summary of knowledge and new perspectives},
  author={Filip Tyl{\vs} and Tom{\'a}{\vs} P{\'a}len{\'i}{\vc}ek and Jiř{\'i} Hor{\'a}{\vc}ek},
  journal={European Neuropsychopharmacology},

Figures and Tables from this paper

Role of psilocybin in the treatment of depression
In view of recent work demonstrating psilocybin’s potential to increase subjective sense of wellbeing and because of its novel mechanism of 5-HT2A serotonin receptor agonism, it is being explored for possible therapeutic utility in mood and anxiety disorders.
Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance
This review aims to discuss metabolism of psilocybin and psilocin, by presenting all major and minor psychoactive metabolites, with clinical and forensic relevance in diagnosis.
Psilocybin for Treating Psychiatric Disorders: Is it a Psychonaut Legend or a Promising Therapeutic Perspective?
Psychedelics extracted by plants have been used in religious, spiritual and mystic practices for millennia. In 1957, Dr. Hofmann have identified and synthesized the prodrug psilocybin, a substance
Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective?
Psychedelics extracted from plants have been used in religious, spiritual, and mystic practices for millennia. In 1957, Dr. Hofmann identified and synthesized the prodrug psilocybin, a substance
DARK Classics in Chemical Neuroscience: Psilocybin.
Preliminary studies with psilocybin have shown promise as potential for the treatment of obsessive compulsive disorder, alcohol addiction, tobacco addiction, and major depressive disorder, and thetreatment of depression in terminally ill cancer patients.
The Therapeutic Potential of Psilocybin
The potential of psilocybin in the treatment of neuropsychiatry-related conditions is explored, examining recent advances as well as current research.
Psychedelic drugs—a new era in

  • D. Nutt
  • Psychology, Medicine
    Dialogues in clinical neuroscience
  • 2019
The renaissance of classical psychedelic drugs such as psilocybin and LSD plus 3,4-methylene dioxymethamphetamine (MDMA—ecstasy) in psychiatric research is covered, which is likely to see these medicines approved for clinical practice soon afterwards.
Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years
A systematic review of clinical trials published from 1990 until 2015 concluded that ayahuasca, psilocybin and LSD may be useful pharmacological tools for the treatment of drug dependence, and anxiety and mood disorders, especially in treatment-resistant patients.


The pharmacology of psilocybin
All the available pharmacological data about psilocybin are presented and its still growing capacity for abuse and the widely dispersed data are presented.
Psilocybin und Psilocin, zwei psychotrope Wirkstoffe aus mexikanischen Rauschpilzen
The psychotropically active principles of the Mexican hallucinogenic fungus Psilocybe maxicana HEIM have been isolated and obtained in crystalline form and are present in the fruit bodies, the artificially cultivated mycelium and in the sclerotia.
Animal models of serotonergic psychedelics.
The behavioral effects induced by psychedelic drugs in rodent models are reviewed, the translational potential of these findings are discussed, and areas where further research is needed to better understand the molecular mechanisms and neuronal circuits underlying their neuropsychological effects are defined.
Can psychedelics have a role in psychiatry once again?
  • B. Sessa
  • Psychology
    The British journal of psychiatry : the journal of mental science
  • 2005
Psychedelic or hallucinogenic drugs such as lysergic acid diethylamide (LSD), 3,4,5-trimethoxy-β-phenethylamine (mescaline), psilocybin, 3,4-methylenedioxymethamphetamine (MDMA),
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.
In a controlled clinical environment, psilocybin was safely used in subjects with OCD and was associated with acute reductions in core OCD symptoms in several subjects.
The behavioral pharmacology of hallucinogens.
  • R. Strassman
  • Psychology, Medicine
    The Journal of nervous and mental disease
  • 1984
The basic pharmacology of the major synthetic psychedelic compounds (primarily lysergic acid diethylamide [LSD]-25) is described and reference is made to their potentially beneficial psychological effects.
Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies
The results suggest that the administration of moderate doses of psilocybin to healthy, high-functioning and well-prepared subjects in the context of a carefully monitored research environment is associated with an acceptable level of risk.
[Psychedelic experiences at the onset of productive episodes of endogenous psychoses].
The psychedelic-induced ASC is considered to be an appropriate model for the beginning acute endogenous psychotic episode, but not for the schizophrenic disease as a nosological entity.